These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 35137938)

  • 1. Hepatic complications of peptide receptor radionuclide therapy with Lutetium-177 and Yttrium-90 in patients with neuroendocrine neoplasm.
    Bober B; Saracyn M; Lubas A; Kolodziej M; Brodowska-Kania D; Kapusta W; Kaminski G
    Nucl Med Rev Cent East Eur; 2022; 25(1):54-61. PubMed ID: 35137938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early Complications of Radioisotope Therapy with Lutetium-177 and Yttrium-90 in Patients with Neuroendocrine Neoplasms-A Preliminary Study.
    Bober B; Saracyn M; Zaręba K; Lubas A; Mazurkiewicz P; Wilińska E; Kamiński G
    J Clin Med; 2022 Feb; 11(4):. PubMed ID: 35207193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog
    Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X
    J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?
    Kunikowska J; Królicki L; Hubalewska-Dydejczyk A; Mikołajczak R; Sowa-Staszczak A; Pawlak D
    Eur J Nucl Med Mol Imaging; 2011 Oct; 38(10):1788-97. PubMed ID: 21553086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Lu-177 DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Unresectable or Metastatic Neuroendocrine Tumors in Korea.
    Shin Y; Moon BH; Ryoo BY; Chang HM; Kim KP; Hong YS; Kim TW; Ryu JS; Kim YI; Yoo C
    Target Oncol; 2024 Jan; 19(1):41-49. PubMed ID: 38108953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term results and tolerability of tandem peptide receptor radionuclide therapy with
    Kunikowska J; Pawlak D; Bąk MI; Kos-Kudła B; Mikołajczak R; Królicki L
    Ann Nucl Med; 2017 Jun; 31(5):347-356. PubMed ID: 28316066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptide Receptor Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors - from oncology perspective.
    Kolasińska-Ćwikła A; Łowczak A; Maciejkiewicz KM; Ćwikła JB
    Nucl Med Rev Cent East Eur; 2018; 21(2):. PubMed ID: 29741203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Feasibility and utility of re-treatment with (177)Lu-DOTATATE in GEP-NENs relapsed after treatment with (90)Y-DOTATOC.
    Severi S; Sansovini M; Ianniello A; Bodei L; Nicolini S; Ibrahim T; Di Iorio V; D'Errico V; Caroli P; Monti M; Paganelli G
    Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1955-63. PubMed ID: 26112388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Symptomatic Control of Refractory Carcinoid Syndrome.
    Zandee WT; Brabander T; Blažević A; Minczeles NS; Feelders RA; de Herder WW; Hofland J
    J Clin Endocrinol Metab; 2021 Aug; 106(9):e3665-e3672. PubMed ID: 33942075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different technical possibilities of post-therapeutic tandem 90Y/ /177Lu-DOTATATE imaging.
    Kunikowska J; Bajera A; Sawicka M; Czwarnowski P; Pawłowicz B; Aksamit D; Pawlak D; Królicki L
    Nucl Med Rev Cent East Eur; 2013; 16(2):70-4. PubMed ID: 24068636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nephrotoxicity after PRRT - still a serious clinical problem? Renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATATE and 90Y/177Lu-DOTATATE.
    Kunikowska J; Królicki L; Sowa-Staszczak A; Pawlak D; Hubalewska-Dydejczyk A; Mikołajczak R
    Endokrynol Pol; 2013; 64(1):13-20. PubMed ID: 23450442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Analysis for Therapeutic Doses of Patients with Neuroendocrine Tumor Treated with Lutetium 177 (
    Kovan B; Özkan ZG; Demir B; Tunçman D; Işik EG; Şimşek DH; Büyükkaya F; Türkmen C; Şanli Y
    Cancer Biother Radiopharm; 2022 Feb; 37(1):17-22. PubMed ID: 34134512
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety and Effectiveness of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy After Regional Hepatic Embolization in Patients With Somatostatin-Expressing Neuroendocrine Tumors.
    Hamiditabar M; Ali M; Bolek L; Vahdati G; Tworowska I; Delpassand ES
    Clin Nucl Med; 2017 Nov; 42(11):822-828. PubMed ID: 28832377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term Nephrotoxicity after PRRT: Myth or Reality.
    Baum RP; Fan X; Jakobsson V; Yu F; Schuchardt C; Chen X; Zhang J
    Theranostics; 2024; 14(2):451-459. PubMed ID: 38169589
    [No Abstract]   [Full Text] [Related]  

  • 15. Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience.
    Delpassand ES; Samarghandi A; Zamanian S; Wolin EM; Hamiditabar M; Espenan GD; Erion JL; O'Dorisio TM; Kvols LK; Simon J; Wolfangel R; Camp A; Krenning EP; Mojtahedi A
    Pancreas; 2014 May; 43(4):518-25. PubMed ID: 24632546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tandem peptide receptor radionuclide therapy using
    Kunikowska J; Zemczak A; Kołodziej M; Gut P; Łoń I; Pawlak D; Mikołajczak R; Kamiński G; Ruchała M; Kos-Kudła B; Królicki L
    Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):922-933. PubMed ID: 31980909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 177Lu-DOTATATE PRRT in Patients with Metastatic Neuroendocrine Tumor and a Single Functioning Kidney: Tolerability and Effect on Renal Function.
    Ranade R; Basu S
    J Nucl Med Technol; 2016 Jun; 44(2):65-9. PubMed ID: 26848166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extravasation After [ 177 Lu]Lu-HA-DOTATATE Therapy.
    de Vries-Huizing DMV; Cheung ZJ; Hendrikx JJMA; Donswijk ML; Versleijen MWJ
    Clin Nucl Med; 2024 May; 49(5):454-456. PubMed ID: 38465961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nephrotoxicity/renal failure after therapy with 90Yttrium- and 177Lutetium-radiolabeled somatostatin analogs in different types of neuroendocrine tumors: a systematic review.
    Stolniceanu CR; Nistor I; Bilha SC; Constantin V; Simona V; Matovic M; Stefanescu C; Covic A
    Nucl Med Commun; 2020 Jul; 41(7):601-617. PubMed ID: 32404645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose escalation of an Evans blue-modified radiolabeled somatostatin analog
    Liu Q; Cheng Y; Zang J; Sui H; Wang H; Jacobson O; Zhu Z; Chen X
    Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):947-957. PubMed ID: 31832728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.